Abstract | INTRODUCTION: METHODS: An intravenous tumor cell injection lung metastases model was used. Sixty female A/J mice were divided into six equal groups designated (1) anesthesia control (AC), (2) AC with Flt3 ligand (ACFlt3), (3) sham laparotomy (OP), (4) OP with Flt3 ligand (OPFlt3), (5) OP with vaccine (OPVac), and (6) OP with Flt3 ligand and vaccine (OPFlt3Vac). Groups 2, 4, and 6 received daily intraperitoneal injections of Flt3 ligand (10 microg/dose with carrier) for 5 days before and 5 days after surgery. Groups 1 and 3 received similar injections of saline on the same schedule. Groups 5 and 6 were vaccinated with irradiated whole Ta3Ha tumor cells intraperitoneally three times before and twice after surgery. Immediately after surgery, all mice were injected with 10(5) Ta3Ha tumor cells via a tail vein. After 14 days, the mice were sacrificed and their lungs and tracheas were excised en bloc. Specimens were stained and counterstained with India ink and Fekete solution, and surface metastases were counted by a blinded observer. Differences between study groups were determined by analysis of variance. The peritumoral inflammatory cell infiltrate of some Flt3 and control specimens was also assessed. RESULTS: Regarding laparotomy, Flt3 ligand (mean, 1.22 metastases), whole cell vaccine (1.12 metastases), and the combination of these two agents (0.1 metastases) were each effective in significantly decreasing the number of surface lung metastases compared with surgery alone (9.88 metastases, P < .05 for all comparisons). There were no differences between the various treatment groups in regards to number of metastases. Only the combination of Flt3 and the vaccine significantly lowered the incidence of tumors (number of mice with > or =1 tumors). Histologic analysis revealed that the Flt3-treated mice demonstrated increased numbers of antigen-presenting cells surrounding the tumors compared with controls. CONCLUSIONS:
|
Authors | Joseph J Carter, Daniel L Feingold, Anthony Oh, Irena Kirman, Peer Wildbrett, George Stapleton, Zishan Asi, Ryan Fowler, Govind Bhagat, Emina H Huang, Robert L Fine, Richard L Whelan |
Journal | Surgical innovation
(Surg Innov)
Vol. 13
Issue 1
Pg. 41-7
(Mar 2006)
ISSN: 1553-3506 [Print] United States |
PMID | 16708154
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adjuvants, Immunologic
- Cancer Vaccines
- Membrane Proteins
- flt3 ligand protein
|
Topics |
- Adenocarcinoma
- Adjuvants, Immunologic
(pharmacology)
- Analysis of Variance
- Animals
- Cancer Vaccines
(pharmacology)
- Female
- Laparotomy
- Lung Neoplasms
(prevention & control, secondary)
- Mammary Neoplasms, Experimental
(pathology)
- Membrane Proteins
(pharmacology)
- Mice
- Random Allocation
|